Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma.

Berlow NE, Rikhi R, Geltzeiler M, Abraham J, Svalina MN, Davis LE, Wise E, Mancini M, Noujaim J, Mansoor A, Quist MJ, Matlock KL, Goros MW, Hernandez BS, Doung YC, Thway K, Tsukahara T, Nishio J, Huang ET, Airhart S, Bult CJ, Gandour-Edwards R, Maki RG, Jones RL, Michalek JE, Milovancev M, Ghosh S, Pal R, Keller C.

BMC Cancer. 2019 Jun 17;19(1):593. doi: 10.1186/s12885-019-5681-6.

2.

IL-13 receptors as possible therapeutic targets in diffuse intrinsic pontine glioma.

Berlow NE, Svalina MN, Quist MJ, Settelmeyer TP, Zherebitskiy V, Kogiso M, Qi L, Du Y, Hawkins CE, Hulleman E, Li XN, Gultekin SH, Keller C.

PLoS One. 2018 Apr 5;13(4):e0193565. doi: 10.1371/journal.pone.0193565. eCollection 2018.

3.

Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy.

Hovelson DH, Liu CJ, Wang Y, Kang Q, Henderson J, Gursky A, Brockman S, Ramnath N, Krauss JC, Talpaz M, Kandarpa M, Chugh R, Tuck M, Herman K, Grasso CS, Quist MJ, Feng FY, Haakenson C, Langmore J, Kamberov E, Tesmer T, Husain H, Lonigro RJ, Robinson D, Smith DC, Alva AS, Hussain MH, Chinnaiyan AM, Tewari M, Mills RE, Morgan TM, Tomlins SA.

Oncotarget. 2017 Sep 22;8(52):89848-89866. doi: 10.18632/oncotarget.21163. eCollection 2017 Oct 27.

4.

Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities.

Stires H, Heckler MM, Fu X, Li Z, Grasso CS, Quist MJ, Lewis JA, Klimach U, Zwart A, Mahajan A, Győrffy B, Cavalli LR, Riggins RB.

Mol Cell Endocrinol. 2018 Aug 15;471:105-117. doi: 10.1016/j.mce.2017.09.024. Epub 2017 Sep 19.

5.

Functionally defined therapeutic targets in diffuse intrinsic pontine glioma.

Grasso CS, Tang Y, Truffaux N, Berlow NE, Liu L, Debily MA, Quist MJ, Davis LE, Huang EC, Woo PJ, Ponnuswami A, Chen S, Johung TB, Sun W, Kogiso M, Du Y, Qi L, Huang Y, Hütt-Cabezas M, Warren KE, Le Dret L, Meltzer PS, Mao H, Quezado M, van Vuurden DG, Abraham J, Fouladi M, Svalina MN, Wang N, Hawkins C, Nazarian J, Alonso MM, Raabe EH, Hulleman E, Spellman PT, Li XN, Keller C, Pal R, Grill J, Monje M.

Nat Med. 2015 Jul;21(7):827. doi: 10.1038/nm0715-827a. No abstract available.

PMID:
26151328
6.

Functionally defined therapeutic targets in diffuse intrinsic pontine glioma.

Grasso CS, Tang Y, Truffaux N, Berlow NE, Liu L, Debily MA, Quist MJ, Davis LE, Huang EC, Woo PJ, Ponnuswami A, Chen S, Johung TB, Sun W, Kogiso M, Du Y, Qi L, Huang Y, Hütt-Cabezas M, Warren KE, Le Dret L, Meltzer PS, Mao H, Quezado M, van Vuurden DG, Abraham J, Fouladi M, Svalina MN, Wang N, Hawkins C, Nazarian J, Alonso MM, Raabe EH, Hulleman E, Spellman PT, Li XN, Keller C, Pal R, Grill J, Monje M.

Nat Med. 2015 Jun;21(6):555-9. doi: 10.1038/nm.3855. Epub 2015 May 4. Erratum in: Nat Med. 2015 Jul;21(7):827.

7.

Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.

Hovelson DH, McDaniel AS, Cani AK, Johnson B, Rhodes K, Williams PD, Bandla S, Bien G, Choppa P, Hyland F, Gottimukkala R, Liu G, Manivannan M, Schageman J, Ballesteros-Villagrana E, Grasso CS, Quist MJ, Yadati V, Amin A, Siddiqui J, Betz BL, Knudsen KE, Cooney KA, Feng FY, Roh MH, Nelson PS, Liu CJ, Beer DG, Wyngaard P, Chinnaiyan AM, Sadis S, Rhodes DR, Tomlins SA.

Neoplasia. 2015 Apr;17(4):385-99. doi: 10.1016/j.neo.2015.03.004.

8.

Integrative molecular profiling of routine clinical prostate cancer specimens.

Grasso CS, Cani AK, Hovelson DH, Quist MJ, Douville NJ, Yadati V, Amin AM, Nelson PS, Betz BL, Liu CJ, Knudsen KE, Cooney KA, Feng FY, McDaniel AS, Tomlins SA.

Ann Oncol. 2015 Jun;26(6):1110-8. doi: 10.1093/annonc/mdv134. Epub 2015 Mar 3.

9.

Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.

Cani AK, Hovelson DH, McDaniel AS, Sadis S, Haller MJ, Yadati V, Amin AM, Bratley J, Bandla S, Williams PD, Rhodes K, Liu CJ, Quist MJ, Rhodes DR, Grasso CS, Kleer CG, Tomlins SA.

Mol Cancer Res. 2015 Apr;13(4):613-9. doi: 10.1158/1541-7786.MCR-14-0578. Epub 2015 Jan 15.

10.

Tumor evolution and progression in multifocal and paired non-invasive/invasive urothelial carcinoma.

Warrick JI, Hovelson DH, Amin A, Liu CJ, Cani AK, McDaniel AS, Yadati V, Quist MJ, Weizer AZ, Brenner JC, Feng FY, Mehra R, Grasso CS, Tomlins SA.

Virchows Arch. 2015 Mar;466(3):297-311. doi: 10.1007/s00428-014-1699-y. Epub 2014 Dec 11.

11.

HRAS mutations are frequent in inverted urothelial neoplasms.

McDaniel AS, Zhai Y, Cho KR, Dhanasekaran SM, Montgomery JS, Palapattu G, Siddiqui J, Morgan T, Alva A, Weizer A, Lee CT, Chinnaiyan AM, Quist MJ, Grasso CS, Tomlins SA, Mehra R.

Hum Pathol. 2014 Sep;45(9):1957-65. doi: 10.1016/j.humpath.2014.06.003. Epub 2014 Jun 18.

12.

Methods and challenges in timing chromosomal abnormalities within cancer samples.

Purdom E, Ho C, Grasso CS, Quist MJ, Cho RJ, Spellman P.

Bioinformatics. 2013 Dec 15;29(24):3113-20. doi: 10.1093/bioinformatics/btt546. Epub 2013 Sep 23.

13.

The mutational landscape of lethal castration-resistant prostate cancer.

Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, Mehra R, Prensner JR, Palanisamy N, Ryslik GA, Vandin F, Raphael BJ, Kunju LP, Rhodes DR, Pienta KJ, Chinnaiyan AM, Tomlins SA.

Nature. 2012 Jul 12;487(7406):239-43. doi: 10.1038/nature11125.

14.

Personalized oncology through integrative high-throughput sequencing: a pilot study.

Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, Kalyana-Sundaram S, Sam L, Balbin OA, Quist MJ, Barrette T, Everett J, Siddiqui J, Kunju LP, Navone N, Araujo JC, Troncoso P, Logothetis CJ, Innis JW, Smith DC, Lao CD, Kim SY, Roberts JS, Gruber SB, Pienta KJ, Talpaz M, Chinnaiyan AM.

Sci Transl Med. 2011 Nov 30;3(111):111ra121. doi: 10.1126/scitranslmed.3003161.

15.

Detection of somatic copy number alterations in cancer using targeted exome capture sequencing.

Lonigro RJ, Grasso CS, Robinson DR, Jing X, Wu YM, Cao X, Quist MJ, Tomlins SA, Pienta KJ, Chinnaiyan AM.

Neoplasia. 2011 Nov;13(11):1019-25.

16.

Improved interobserver agreement for visual detection of active T2 lesions on serial MR scans in multiple sclerosis using image registration.

Tan IL, van Schijndel RA, Fazekas F, Filippi M, Freitag P, Miller DH, Yousry TA, Pouwels PJ, Adèr HJ, Quist MJ, Barkhof F.

J Neurol. 2001 Sep;248(9):789-94.

PMID:
11596784

Supplemental Content

Loading ...
Support Center